NO20042730L - Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft - Google Patents

Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Info

Publication number
NO20042730L
NO20042730L NO20042730A NO20042730A NO20042730L NO 20042730 L NO20042730 L NO 20042730L NO 20042730 A NO20042730 A NO 20042730A NO 20042730 A NO20042730 A NO 20042730A NO 20042730 L NO20042730 L NO 20042730L
Authority
NO
Norway
Prior art keywords
preparation
combination
cancer drug
antineoplastic agents
protein transferase
Prior art date
Application number
NO20042730A
Other languages
English (en)
Norwegian (no)
Inventor
David L Cutler
Michael L Meyers
Charles Baum
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042730L publication Critical patent/NO20042730L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042730A 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft NO20042730L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
NO20042730L true NO20042730L (no) 2004-06-29

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042730A NO20042730L (no) 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN101181269A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
KR20250102088A (ko) 2022-11-09 2025-07-04 메르크 파텐트 게엠베하 선천성 항종양 면역을 유발시키기 위한 면역-자극제로서 Toll-유사 수용체 7 효현제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
BR0214564A (pt) 2004-11-09
EP1448268A2 (en) 2004-08-25
WO2003047697A3 (en) 2003-10-30
US20030185831A1 (en) 2003-10-02
CN101181269A (zh) 2008-05-21
MXPA04005207A (es) 2004-08-19
HUP0402401A2 (hu) 2005-03-29
CA2468839A1 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17
CN1617755A (zh) 2005-05-18
ZA200403737B (en) 2005-05-23
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
EE04579B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
NO20030627D0 (no) Hydrogel-drevet medikament doseringsform
DE69925133D1 (de) Pyrrolobenzodiazepine
DE50212273D1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
NO20003219L (no) Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
NO20032909L (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
ID28427A (id) Benda penyerap cairan tubuh sekali pakai
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
ITTO20010008A0 (it) Formulazione farmaceutica
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO20034439L (no) Benzamidinderivater
DE60127002D1 (de) Pharmazeutische zusammensetzung
EE05020B1 (et) Glburiidi ravimkoostis
EP1411904A4 (en) PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE
NO20042730L (no) Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft
EE05333B1 (et) Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ATE366128T1 (de) Pharmazeutische zusammensetzung
SI1475379T1 (sl) Uporaba derivatov skopinskega estra za pripravo zdravil
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application